Genetron Health Enters Exclusive Global Licensing Agreement with ImmuQuad Biotechnologies to Develop and Commercialize Minimal Residual Disease Assays in Hematologic Cancer

    NEXT STORY
    MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy
    PREV STORY
    COVID-19 Impact on Social and Emotional Learning (SEL) Market – Global Forecast to 2026
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    ERYTECH annonce la publication des résultats de son étude de phase 2b avec eryaspase dans le traitement du cancer métastatique du pancréas dans l’European Journal of Cancer

    author_avatar
    NASDAQ Market News

    Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2

    CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. ...

    author_avatar
    NASDAQ Market News

    Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology (ESMO) Congress

    Supinoxin™ is well tolerated and shows preliminary evidence of clinical activity in difficult to ...

    author_avatar
    NASDAQ Market News